First in human lung transplantation: adenosine a2a receptor agonist (regadenoson)

Background: Currently, no clinically available treatment exists for ischemia-reperfusion injury (IRI) following lung transplantation. Pre-clinical animal models have shown adenosine 2A receptor (A2AR) agonists are effective treatment options for reducing IRI. The purpose of this first in human study was to conduct a Phase I clinical trial to evaluate the safety of continuous infusion of an A2AR agonist in lung transplant recipients.Methods: An adaptive, 2-stage continual reassessment trial was designed to evaluate the safety of regadenoson (A2AR agonist) in the setting of lung transplantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research